Integrated Biotherapeutics, LLC

Integrated Biotherapeutics, LLC (doing business as IBT Bio Services), a self-certified small disadvantaged business based in Rockville, Maryland, delivers specialized biomedical research and laboratory services to federal health agencies as a prime contractor on 94% of recent awards, with concentrated exposure to NIH intramural and extramural programs and emerging work in vaccine efficacy testing and correlates-of-protection studies for defense agencies.

IBT Bio Services operates as a limited liability partnership and manufacturer of goods, competing predominantly in full-and-open procurements without set-aside designation. The vendor's capability footprint centers on quantitative cytokine profiling using high-throughput Luminex immunoassay, sample preparation and bead-based immunoassay execution, in-vivo vaccine efficacy testing in animal models, laboratory and diagnostic testing services, and biomedical R&D support for infectious disease and oncology programs. Representative work includes a $75,000 firm fixed-price purchase order with the National Institute of Environmental Health Sciences (awarded September 2026) for specialized cytokine profiling services to the Viral Vector Core; a $46,090 purchase order from Veterans Integrated Service Network 10 (June 2026) for medical R&D services in Ann Arbor, Michigan; a $17,964 purchase order from the National Cancer Institute (February 2025) for laboratory and testing services; and prior orders from NCI covering mouse efficacy studies for a phage-vector neuroblastoma vaccine construct ($16,869, August 2022) and lambda phage vaccine engineering testing with COVID-19 spike protein antigens ($16,869, August 2022).

Customer concentration is heavily skewed to health research. The Department of Health and Human Services National Institutes of Health dominates the active footprint: the National Institute of Allergy and Infectious Diseases accounts for 13 awards (the largest award count among named customers), while NIH's broad entity carries 6 additional awards and NIAID's DEA OA Acquisitions arm alone anchors $59.1 million in potential value (a single contract). The National Cancer Institute holds 3 awards ($52 thousand combined potential value), and the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response accounts for 2 awards. Two defense customers have emerged: the Defense Threat Reduction Agency carries $8.4 million in potential value (correlates-of-protection studies for Sudan virus vaccine development via a subcontract under Advanced Technology International, awarded October 2024), and the Army Medical Command holds $840 thousand. Across all 35 recent awards, 80% cluster within five named agencies, with the broad HHS umbrella accounting for most activity.

IBT Bio Services sits on one named indefinite delivery vehicle: IDC 75A50123D00003 (one task order). The vendor operates primarily as a prime contractor but engages subcontractors on a material basis — across SCI-reportable prime contracts, subcontractors account for an average 27% of total contractor hours, with four named subcontractors reported. SCI-reported invoiced revenue totaled $1.5 million in FY2022 (the only fiscal year with prime SCI records above the $150,000 reporting threshold), delivered by 2.9 FTEs on contract records; that metric dropped to 0.1 FTEs in FY2024 on one sub-engagement record, reflecting a shift toward smaller purchase-order activity below the SCI reporting floor. Government-paid rates on SCI-reportable prime contracts held steady at a median of $181.92 per hour. Awards per year show sparse recent volume (two awards in 2020, two in 2022, one in 2024, one in 2025, two in 2026), and only $121 thousand in combined potential value reaches ultimate completion inside the next twenty-four months, creating minimal near-term recompete exposure.